5.90
0.46 (8.36%)
| Previous Close | 5.45 |
| Volume | 138,340 |
| Price / Earnings (Forward) | 5.92 |
| Price / Sales | 1.57 |
| 52 Weeks Range |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Phathom Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | -1.7 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -1.7 |
| Timing 35% | -0.5 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.4% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | 2.6 |
| Final Score | -1.17 |
Select this tab to load the latest available analysis.
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2026 | 7,464,572 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |